DI GIACOMO ANNA MARIA | Professor page

Ascierto, P.a., Del Vecchio, M., Merelli, B., Gogas, H., Arance, A.m., Dalle, S., et al. (2026). Nivolumab for Resected Stage III or IV Melanoma at 9 Years. THE NEW ENGLAND JOURNAL OF MEDICINE [10.1056/NEJMoa2504966]. - view more
Di Giacomo, A.M., Bartalini, S., D'Alonzo, V., Cerase, A., Cutarella, S., Rossi, G., et al. (2025). Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team. EUROPEAN JOURNAL OF CANCER, 228 [10.1016/j.ejca.2025.115707]. - view more
Buhrer, E., Glassee, N., Kicinski, M., Kennedy, O.J., Blank, C.U., Long, G.V., et al. (2025). Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. EJC SKIN CANCER, 3 [10.1016/j.ejcskn.2025.100727]. - view more
Kennedy, O.J., Glassee, N., Kicinski, M., Buhrer, E., Valpione, S., Gandini, S., et al. (2025). Prognostic and predictive importance of body mass index and type 2 diabetes in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. EJC SKIN CANCER, 3 [10.1016/j.ejcskn.2025.100284]. - view more
Tini, P., Cinelli, E., Yavorska, M., Donnini, F., Marampon, F., Pastina, P., et al. (2025). Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol. JOURNAL OF NEURO-ONCOLOGY, 171(2), 413-421 [10.1007/s11060-024-04862-5]. - view more

All publications